After RE-Y90, there were no complications and the patients were discharged after 24 hours.

Control Computed Axial Tomography was performed with good response, without disease progression at 3 and 6 months, asymptomatic.

**Conclusions:** RE-Y90 for the treatment of BCLC stage B HCC is a good therapeutic option in well selected patient.

**Conflicts of interest:** The authors have no conflicts of interest to declare.



## https://doi.org/10.1016/j.aohep.2020.08.046

#### 46

## Aspartate aminotransferase as predictor of severity in SARSCoV-2 infection: linear regression model

A. Servín-Caamaño, D. Reyes-Herrera,

- A. Flores-López, E.J.A. Robiou-Vivero,
- F. Martínez-Rivera, V. Galindo-Hernández,
- C. Casillas-Suárez, O. Chapa-Azuela,
- A. Chávez-Morales, V.H. Rosales-Salyano,
- B. Jiménez-Bobadilla, M.L. Hernández-Medel,
- B. Orozco-Zúñiga, J.R. Zacarías-Ezzat,
- S. Camacho-Hernández, J.L. Pérez-Hernández,

F. Higuera-de la Tijera

Hospital General de México "Dr. Eduardo Liceaga", México

**Background and aim:** Some patients with SARSCov-2 infection develop severe disease (SARS); however, the factors associated with severity are not yet fully understood. Some reports indicate that liver injury may be a poor prognostic factor. AIM: To identify the biochemical factors related to the development of SARS with mechanical ventilation (MV) requirement in patients with SARSCov-2 and COVID-19.

**Methods.** Type of study: Observational. Cohort study. Procedure: Data from COVID-19 patients were collected at admission time to a tertiary care center. Differential factors were identified between seriously ill SARS+MV patients versus stable patients without MV. Transformation to the natural logarithm of significant variables was performed and multiple linear regression was applied, then a predictive model of severity called AAD (*Age-AST-D dimer*) was constructed.

**Results:** 166 patients were included, 114(68.7%) men, mean age  $50.6 \pm 13.3$  years-old, 27(16.3%) developed SARS+MV. In the comparative analysis between those with SARS+MV versus stable patients without MV we found significant raises of ALT (225.4 \pm 341.2 vs. 41.3 \pm 41.1; P=0.003), AST 325.3 \pm 382.4 vs. 52.8 \pm 47.1; P=0.001), LDH (764.6 \pm 401.9 vs. 461.0 \pm 185.6; P=0.001), D dimer (7765 \pm 9109 vs. 1871 \pm 4146; P=0.003), age (58.6 \pm 12.7 vs. 49.1 \pm 12.8; P=0-001). The results of the regression are shown in the Table, where model 3 was the one that best explained the development of SARS+MV; with these variables was constructed the model called AAD, where: [AAD = 3.896 + ln(age)x-0.218 + ln(AST)x-0.185 + ln(DD)x0.070], where a value  $\leq$  2.75 had sensitivity = 0.797 and 1-specificity = 0.391, AUROC = 0.74 (95%CI:

0.62-0.86; *P*<0.0001), to predict the risk of developing SARS+MV (OR = 5.8, 95%CI: 2.2-15.4; *P*=0.001).

**Conclusions:** Elevation of AST (probable marker of liver damage) is an important predictor of progression to SARS, together with elevation of D-dimer and age early (at admission) and efficiently predict which patients will potentially require MV.

**Conflicts of interest:** The authors have no conflicts of interest to declare.

Multiple linear regression models predictive of SARS development in patients with COVID-19 and	
requirement for intubation	

requirement for intubution										
Non-standarized Coeficients	Standarized Coeficients		Standarized Coeficients		Р	95% Confi Interval fo	95% Confidence Interval for B		Colinearity statistics	
Error Desv.	Beta			Inferior limit	Superior limit	Tolerance	VIF			
2.721	.131		.000	2.462	2.980					
229	.033	512	.000	293	164	1.000	1.000			
3.161	.198		.000	2.770	3.551					
194	.034	435	.000	261	127	.878	1.139			
081	.028	221	.004	135	026	.878	1.139			
3.896	.414		.000	3.077	4.714					
185	.034	413	.000	252	118	.860	1.163			
070	.028	190	.014	125	014	.844	1.185			
218	.108	148	.046	433	004	.915	1.093			
	Non-standarized Coeficients Error Desv. 2.721 229 3.161 194 081 3.896 185 070 218	Non-standarized  Standarized    Coefficients  Coefficients    Error Desv.  Beta    2.721  .131    -229  .033    3.161  .198    -194  .034   081  .028    3.896  .414   185  .034   070  .028	Non-standarized Coeficients  Standarized Coeficients    Error Desv.  Beta    2.721  .131   229  .033 512    3.161  .198   194  .034 435   081  .028 221    3.896  .414   185  .034 413   070  .028 198	Non-standarized Coeficients  Standarized Coeficients  P    2.721  .131  .000    -229  .033 512  .000    3.161  .198  .000  .001   081  .028 221  .004   081  .028 221  .004   185  .034 413  .000   195  .034 413  .001   218  .108 148  .046	Non-standarized Coeficients  Standarized Coeficients  P  95% Confi Interval fe    Error Desv.  Beta  Inferior limit    2.721  .131  .000  2.462   229  .033 512  .000 293    3.161  .198  .000  2.770   194  .034 435  .000 261   081  .028 221  .004 135    3.896  .414  .000  3.077  .185  .034  .413  .000 252   070  .028  .190  .014 125  .218  .108 148  .046 433	Non-standarized Coeficients  Standarized Coeficients  P Coeficients  95% Confidence Interval for B    2.721  .131  .000  2.462  2.980    3.161  .198  .000 223 164    3.161  .198  .000  2.770  3.551   081  .028 221  .004 135 026    3.896  .414  .000  3.077  4.714   185  .034 413  .000 252 118   070  .028 190  .014 125 014   218  .108  .148  .046 433  .004	Non-standarized Coeficients  Standarized Coeficients  P  95% Confidence Interval for B  Colinearit statistics    2.721  .131  .000  2.462  2.980  Tolerance   229  .033 512  .000 263 164  1.000    3.161  .198  .000  2.770  3.551  .000 261 127  .878   081  .028 221  .004 135 026  .878    3.896  .414  .000  3.077  4.714  .185  .034 413  .000 252 118  .860   070  .028 190  .014 125 014  .844   185  .034 413  .000 252 118  .860   070  .028 190  .014 125 014  .844			

AST, aspartate aminotransferase; C, constant; DD, D dimer; VIF, variance inflation factors.

Resume of the model:

R = 0.512,  $r^2 = 0.262$ ,  $r^2$  adjusted = 0.256, standard error = 0.331.

R = 0.552, r<sup>2</sup> = 0.305, r<sup>2</sup> adjusted = 0.294, standard error = 0.322.

R = 0.570,  $r^2$  = 0.325,  $r^2$  adjusted = 0.310, standard error = 0.318. Durbin-Watson = 1.53.





## https://doi.org/10.1016/j.aohep.2020.08.047

#### 47

# Classification of alcohol consumption pattern in the Mexican population

M. Martínez-Castillo, D. Rosique-Oramas, Z. Medina Ávila, G. Gutiérrez-Reyes

Liver, Pancreas and Motility laboratory, Unit of Experimental Medicine, School of Medicine, National Autonomous University of Mexico (UNAM), General Hospital of Mexico, Mexico City

**Background and aim:** The evaluation of alcohol consumption is estimate by the evaluation of frequency and the concentration of

